Results 131 to 140 of about 1,300 (156)

Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit

Clinical Therapeutics, 2022
Jipan Xie, Louis Garrison
exaly  

Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review

Heart Lung and Circulation, 2023
Stephanie Fabara, Hashim Al-Ani
exaly  

Mavacamten

Reactions Weekly, 2018
openaire   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China

JAMA Cardiology, 2023
openaire   +2 more sources

Effect of Chronopharmacology and Food on in Vivo Pharmacokinetic Profile of Mavacamten

Bioanalysis, 2023
Rajesh Sonti, Dandekar Mp, Siva Nageswara Rao Gajula   +2 more
exaly  

MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: EFFECTIVE, BUT AFFORDABLE?

Journal of the American College of Cardiology, 2023
Shivani Hanchate, Allison Perry, Karen McClean, Christopher M. Kramer, Michael Ayers   +4 more
openaire   +1 more source

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide

Pharmacotherapy, 2023
Andrew Willeford, Jorge Silva Enciso
exaly  

Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy

Expert Opinion on Investigational Drugs, 2020
Albree Tower-Rader, Jay Ramchand, Milind Desai   +2 more
exaly  

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
Milind Y. Desai, Anjali Owens, Pablo Garcia-Pavia, Theodore Abraham, Steve E. Nissen, Philippe Chevalier, Andrew Wang, Juliana De Souza, Richard Bach, Antoine Bondue, Zhiqun Gong, Ronald Aronson, Victoria Florea, Iacopo Olivotto   +13 more
  +4 more sources

Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

European Journal of Heart Failure, 2023
Matthew T Wheeler, Perry M Elliott
exaly